Springworks Therapeutics
Highly Engaged Employees
Business Services · Connecticut, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
100 Washington Blvd, Stamford, Connectic...Phone Number
(203) 883-9490Website
www.springworkstx.comRevenue
$191.6 MillionIndustry
About Springworks Therapeutics
Springworks Therapeutics Org Chart
Head Worldwide Medical Affairs & Member Leade...
Global Patient Advocacy Senior Director
Global Senior Director, Medical Research Oper...
Senior Director, US Medical Science Liaison T...
Senior Director, Clinical Pharmacology
Senior Director, Toxicology
Global Director, Medical Research
Global Medical Director, Pharmacovigilance
Senior Medical Director
Is Springworks Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Springworks Therapeutics had a recent Job posting/layoffs
Check out if Springworks Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Springworks Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Springworks Therapeutics recently announced quarterly report
Check if Springworks Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Springworks Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Springworks Therapeutics
Springworks Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Springworks Therapeutics
Compare insights from companies similar to Springworks Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Springworks Therapeutics
Company Profile Activity
Activity Insights
Springworks Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Springworks Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Springworks Therapeutics.
Springworks Therapeutics financials insights
Gather financial insights about Springworks Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$75M
Share Placement
$225M
Springworks Therapeutics Tech Stack
A closer look at the technologies used by Springworks Therapeutics
Most Recent Scoops
Springworks Therapeutics News & Media
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile –European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsMerck KGaA's Strategic Debt Financing and Acquisition of SpringWorks Therapeutics
Merck KGaA's Strategic Debt Financing and Acquisition of SpringWorks Therapeutics: A High-Conviction Play in Rare Disease InnovationEuropean Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – – EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Springworks Therapeutics
Founded in 2017. SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science. It pioneers efficient pathways for drug development and serves patients with rare diseases and cancer. SpringWorks Therapeutics is headquartered in Stamford, Connecticut.... Read More